The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.
Bottom Line: Narrative analyses revealed consistent evidence for a reduction in mortality, especially when convalescent plasma is administered early after symptom onset.Exploratory post hoc meta-analysis showed a statistically significant reduction in the pooled odds of mortality following treatment, compared with placebo or no therapy (odds ratio, 0.25; 95% confidence interval, .14-.45; I(2) = 0%).Convalescent plasma may reduce mortality and appears safe.
Affiliation: East Midlands Centre, Public Health England.Show MeSH
Related in: MedlinePlus
Mentions: The post hoc meta-analysis evaluated pooled data from 8 comparative studies: 2 studies of SARS-CoV infection [32, 46], 2 of influenza A(H1N1)pdm09 infection [30, 48], 1 of avian influenza A(H5N1) infection , and 3 of Spanish influenza A(H1N1) infection [33, 38, 47]. There was a statistically significance lower risk of mortality in the group treated with convalescent plasma or serum (pooled OR, 0.25; 95% CI, .14 to .45; P < .001; I2 = 0%; Figure 3). Examination of the funnel plot and findings of the Egger test showed no evidence of publication bias. Sensitivity analyses that excluded studies with ≤5 cases demonstrated little variation in the pooled OR or change in statistical heterogeneity (Figure 4).Figure 3.